Pharmacy and Biomedical Sciences
Profile
Internal memberships / posts
School Library Representative
School Disability Officer
Facilitator for inter-professional learning
External memberships / posts
Fellow of the Higher Education Academy
Clinical and Laboratory Standards Institute
Key teaching responsibilities
Level 2: Introduction to microbiology and microbial pathogenicity
Level 3: Antimicrobial chemotherapy - theory and practice, antimicrobial resistance, development and marketing of antimicrobials, management of infectious diseases, aseptic suite training.
Key research interests
Drug lifecycle management, antimicrobial resistance, antimicrobial surveillance, data mining.
Recent Publications
More recent publications
Publications before 2008
Koeth LM, Jacobs MR, Good CE, Bajaksouzian S, Windau A, Jakielaszek C & Saunders KA, Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9,172 respiratory isolates collected worldwide in 2000, Int. J. Infectious Diseases, 8, 362-373, 2004.
Koeth LM, Good CE, Saunders KA & Jakielaszek C, S. pneumoniae in vitro development of resistance to amoxicillin/clavulanic acid, cefaclor, levofloxacin and azithromycin. Int. J. Antimicrobial Agents, 24, 144-149, 2004.
Bouchillon SK, Hoban DJ, Johnson JL, Johnson BM, Butler DL, Saunders KA, Miller MA, Poupard JA, In vitro activity of gemifloxacin and contemporary oral antimicrobial agents against 27247 Gram positive and Gram negative aerobic isolates: a global surveillance study, Int. J. Antimicrobial Agents, 23, 181-196, 2004.
Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Saunders KA, Miller LA & Poupard JA, Comparative in vitro surveillance study of amoxicillin-clavulanic acid and four oral comparators against 21,232 recent clinical isolates from Europe, Eur. J. Clin. Micro. Infectious Diseases, 22, 261-267, 2003.
Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Saunders KA, Miller LA & Poupard JA, Comparative in vitro potency of amoxicillin-clavulanic acid and four oral agents against recent North American clinical isolates from a global surveillance study, Int. J. Antimicrobial Agents, 21, 425-433, 2003.